September 10th, 2007, by David Pascoe | doxycycline, oracea
There has been a lot of copy written about so-called low dose or anti-inflammatory dose doxycycline. This form of antibiotic therapy is one of the more promising recent therapeutic developments ; it will likely become a widely known and available treatment. This recently published paper shows that a daily dose of 40mg of doxycycline is as effective in reducing the lesions of rosacea as …
July 4th, 2007, by David Pascoe | clinical trials, doxycycline, metrogel, oracea
A clinical trial, sponsored by CollaGenex, is recruiting patients to see how Oracea compares to doxycycline (100mg once a day) when combined with metrogel 1%. We can see from a Collagenex annual report that COL-101 was the name for Periostat MR, which then became Oracea. Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens Purpose: To compare the safety and efficacy of two treatment …
January 23rd, 2006, by David Pascoe | doxycycline, ocular rosacea
Another paper confirming the importance of MMP and the inflammation found in ocular and facial rosacea. This follows up on another recent article suggesting that a diagnostic test for ocular rosacea could be based on the “high abundance of oligosaccharides in the tear fluid of patients with ocular rosacea”. MMPs have also been shown as important in the inflammatory pathway in other studies, see …
December 20th, 2005, by David Pascoe | doxycycline, macrolides, tetracyclines
Clarithromycin versus doxycycline in the treatment of rosacea.
International Journal of Dermatology, 1997 Dec;36(12):942-6. Torresani C, Pavesi A, Manara GC, Department of Dermatology, Parma University, Italy.
Forty patients with rosacea were entered into a study comparing clarithromycin with doxycycline in the systemic treatment of mild and severe rosacea.
Results: At the end of the treatment, the overall results provided evidence for a hight clarithromycin efficacy profile in …
October 17th, 2005, by David Pascoe | doxycycline, ocular rosacea
Doxycycline is a broad spectrum antibiotic that chelates metal ions and is frequently used as part of treatment of ocular surface diseases. Its therapeutic value has been attributed to an ability to inhibit matrix metalloproteinase activity and both matrix metalloproteinase and interleukin-1 synthesis. Smith and Cook studied corneal epithelial cell and keratocyte cultures and in this study they demonstrated that the minimum concentration of doxycycline …
|
|
|
|
|
|
|
|
 |